Gene polymorphisms of endothelial nitric oxide synthase enzyme associated with pulmonary hypertension in patients with COPD  by Yildiz, Pinar et al.
Gene polymorphisms of endothelial nitric oxide
synthase enzyme associated with pulmonary
hypertension in patients with COPD
Pinar Yildiza,*, Huseyin Oflazb, Naci Cinec, Nihan Erginel- .Unaltunac,
Faruk Erzenginb, Veysel Yilmaza
aPulmonary Medicine, Yedikule Chest Disease and Chest Surgery Hospital, Istanbul, Turkey
bDepartment of Cardiology, Istanbul School of Medicine, Istanbul, Turkey
cDepartment of Genetics, Institute for Experimental Medical Research, Istanbul University, Istanbul,Turkey
Summary In this cross-sectional controlled study, we aimed to investigate the role of
polymorphisms of the angiotensin-converting enzyme (ACE) and endothelial nitric
oxide synthase (eNOS) genes on pulmonary hypertension (PH) in patients with chronic
obstructive pulmonary disease (COPD). Forty-two (41 male, 1 female, mean age:
627 7 years) COPD patients and 40 (all male, mean age: 607 8 years) healthy
controls were included. Respiratory function tests, arterial blood gases, and
echocardiographic examinations were performed. ACE and eNOS genotypes were
determined using PCR.
The ACE and eNOS genotype distribution was not significantly different between
COPD patients and controls. On comparing pulmonary artery pressures in different
eNOS genotypes, the mean pulmonary artery pressure (Ppa) in patients with the BB
genotype was significantly higher than in patients with the nonBB genotypes
(41.37 17.7mmHg vs. 27.37 11.2mmHg, P ¼ 0:02). However, there was no
difference in ACE genotype distributions between COPD patients with and without
pulmonary hypertension. In stepwise linear regression analysis for predicting
pulmonary artery pressure, PaO2 and polymorphism of eNOS gene were found to be
independent variables.
In conclusion, BB-type polymorphism of the eNOS gene has been associated with PH
in addition to hypoxemia. However, ACE gene polymorphism was not found to be
associated with PH.
& 2003 Elsevier Ltd. All rights reserved.
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Introduction
It has been shown that the endothelial nitric oxide
(NO) system is abnormal in pulmonary hypertension
(PH), both in hypoxic animal models and in
humans.1–8 Nitric oxide synthase (NOS) expression
has been found to correlate with the process of
pulmonary vascular remodeling in hypoxia-induced
PH, and in the absence of eNOS, remodeling and
pulmonary hypertension are induced.9–12 There-
fore, gene polymorphism of eNOS might be relevant
to the pathogenesis of PH in patients with COPD. To
our knowledge, there is no study investigating
possible association of polymorphism of eNOS genes
and PH in COPD patients.
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Angiotensin II has an effect on regulation of
vascular tone and at least half of the variation in
circulating levels are determined genetically. Dele-
tion and insertion type of polymorphisms have been
defined and homozygous deletion type polymorph-
ism (DD genotype) of ACE is associated with
increased circulating and cellular concentrations
of ACE.13 There is limited data on the effect of ACE
gene polymorphism on development of PH in COPD
patients. Recently it was reported that there is a
possible relationship between the deletion–inser-
tion polymorphism in the ACE gene and PH evoked
by exercise challenge in patients with COPD.14 In
the present study, we aimed to investigate the role
of polymorphisms in the ACE and eNOS genes on PH
in patients with COPD.
Materials and methods
Study groups
In this study, 42 (41 male, one female, mean age:
6277 years) COPD patients and 40 age and sex
matched (all male, mean age: 607 8 years) healthy
controls were included. All COPD patients had a
history of smoking (mean total pack-years 34711;
32 of them (76%) ex-smokers; remaining 10 (24%)
were current smokers) and irreversible airflow
limitation. Diagnosis of COPD was made according
to criteria by American Thoracic Society.15 Control
cases had a smoking history (mean total pack-years
29718), but no clinical history of COPD or any
pulmonary symptoms and a FEV1%pred within
normal limits. Twelve (30%) control subjects were
current smokers and the remaining 28 (70%) were
ex-smokers. There was no significant difference
between COPD and control subjects regarding
smoking status and mean total pack-years. COPD
patients and control subjects were all Caucasians
and none of the control subjects were taking any
medications. Patients with systemic hypertension,
amyloidosis, diabetes mellitus, valvular heart dis-
ease, primary myocardial disease, atrial fibrillation
and patients older than 65 years of age were
excluded. The presence of ischemic heart disease
was assessed with history, chest X-ray, electrocar-
diogram, echocardiogram, and exercise testing
when necessary. Patients with ischemic heart
disease were also excluded. All patients with COPD
were clinically stable, and none had a history of
respiratory infection for at least a 4-week period
preceding the enrolment into the study. Broncho-
dilator treatments were ceased 12 h before the
study. Drug treatment regimens were inhaled
anticholinergics (n: 10), inhaled b2-agonists (n: 4)
or both (n: 26). Ten of the patients (24%) were
receiving theophylline therapy as adjunctive treat-
ment. Two patients were not taking any brochodi-
lator treatment at the commencement of the
study. None of the patients were receiving the
long-term oxygen therapy or corticosteroid treat-
ment.
Pulmonary function test
Pulmonary function tests were performed (Sensor
Medics 2400, Holland). Vital capacity (VC), forced
vital capacity (FVC), forced expiratory volume 1
second (FEV1), forced expiratory flow at 25–75% of
FVC (FEF25–75%), and peak expiratory flow rate
(PEFR) were measured. Results were given as
percent of the predicted values calculated from
the reference values reported by the European
Community for Coal and Steel.16 Arterial blood
gases were also obtained simultaneously. PaO2,
PaCO2, pH, HCO3 and oxygen saturation were
analyzed.
Echocardiographic examination
The echocardiographic examination was done with
Hewlett-Packard Sonos 1000 echocardiographic
system equipped with 2.5 and 3.5MHz transducers.
M-Mode and two-dimensional (2D) measurements
were done in accordance to methods recommended
by the American Society of Echocardiography.17,18
Systolic and diastolic dysfunction were diagnosed
with the measurements of fractional shortening
(o0.25) and mitral E/A ratios (o1), isovolumetric
relaxation time (IVRT)4100ms.
Criteria for left ventricular hypertrophy was the
left ventricular mass index (LVMI) 4134 g/m2 for
men and4110 g/m2 for women.19 The cardiac mass
was calculated by the formula derived by Reichek
and Devereux:20
Left ventricle massðgÞ ¼ 1:04ððLVIDd þ IVSd
þLCPWdÞ3 ðLVIDsÞ3Þ  13:6;
where LVIDd is the left ventricular internal dia-
meter in diastole (cm), IVSd is the interventricular
septum thickness in diastole (cm), LVPWd is the left
ventricular posterior wall thickness in diastole
(cm), and LVIDs is the left ventricular internal
diameter in systole (cm).
Standardized cardiac mass was calculated by
dividing it by body surface area, which was derived
from Du Bois formula:
Body surface area
¼ ðweight0:425  height0:725  0:007184Þ:
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Right ventricle wall dimension and diastolic
diameter were detected with 2D echocardiography
method. Tricuspid valve regurgitation was identi-
fied by continuous wave Doppler echocardiography.
Peak pressure gradient was calculated with the
modified Bernoulli equation (P ¼ 4 V2) from the
peak velocity of tricuspid regurgitation signal.
Systolic pulmonary artery pressure was measured
by adding this pressure decrease to measured mean
right atrial pressure.21
Angiotensin-converting enzyme genotype
determination
Genomic DNA was isolated from leucocytes ob-
tained from peripheral venous blood samples using
the method described by Miller et al.22 Sixteenth
intron of the ACE gene was amplified with
polymerase chain reaction (PCR) as described by
Rigat et al.23 In the first PCR, a 490 base pair (bp)
fragment representing the I allele and a 190 bp
fragment representing the D allele were obtained
(sense: 50-CTG GAG ACC ACT CCC ATC CTT TCT-30;
antisense: 50-GAT GTG GCC ATC ACATTC GTC AGAT-
30). A second PCR reaction was necessary for the
confirmation of the ACE DD genotype by an
insertion-specific PCR amplification with the primer
pair of Lindpaintner et al.24 obtained (sense: 50-
TGG GAC CAC AGC GCC CGC CAC TAC-30; antisense:
50-TCG CCA GCC CTC CCATGC CCATAA-30). The first
PCR product was electrophoresed on a 3% agarose
gel. A 1.5% agarose gel was used for visualizing the
second PCR product. The gels were stained with
ethidium bromide and photographed under UV
light.
Analysis of the VNTRs polymorphism of the
eNOS gene
eNOS genotypes were determined by polymerase
chain reaction (PCR) using oligonucleotide primers
(sense: 50-AGGCCCTATGGTAGTGCCTTT-30; anti-
sense: 50-TCTCTTAGTGCTGTGGTCAT-30) that flank
the region of the 27 bp direct repeat in intron 4 as
described previously with minor modifications.25
Reactions were performed in a total volume of 50 ml
containing 500 ng genomic DNA, 10 pmol of each
primer, 0.2mM dNTP, 0.5 U Taq DNA polymerase
(MBI Fermentas Inc., New York, NY), 5 ml PCR buffer
(500mmol/l KCl, 100mmol trihydroxymethylami-
nomethane chloride and 0.8% Nonidet P40; MBI
Fermentas Inc.). The thermocycling procedure
consisted of initial denaturation at 941C for 5min,
35 cycles of denaturation for 1min, annealing at
551C for 1min, and extension at 721C for 1min. The
PCR products were analyzed using 3% agorose gel
electrophoresis and visualized by ethidium bromide
staining.
Both ACE and eNOS genotypes were detected by
a single person (N.C.) who was unaware of the
patients’ clinical and echocardiographic features.
Statistical analysis
Statistical analyses were performed with Statistical
Package Program for Social Sciences (SPSS for
Windows 10.0, Chicago, IL, USA). Values were given
mean 7 SD. Comparisons between groups were
made by unpaired t-test or Mann-Whitney U-test
when data were distributed abnormally. Compar-
isons of the more than two groups were made with
one-way analysis of variance (ANOVA) and Tukey-
HSD test was used for post-hoc analysis. Chi-square
test with Yates correction and Fisher’s exact test
were used for 2 2 contingency tables when
appropriate for non-numerical data. Correlations
between numerical parameters were analyzed with
Spearman’s rho test. In order to predict pulmonary
artery pressure in COPD patients, age, PaO2,
predicted FEV1 and eNOS genotypes were included
as independent variable in stepwise linear regres-
sion analysis. P-values less than 0.05 were accepted
as significant.
Results
There was no difference in age and sex distribution
between COPD patients and control groups. Results
of the demographic features, pulmonary function
tests, arterial blood gases and echocardiographic
examinations were given in Table 1. COPD patients
were staged on the basis of airflow obstruction
using the criteria of the ATS: eight patients (19%)
had an FEV1X50% pred, 18 patients (42%) had an
FEV1 35–49%pred, and the remaining 16 (39%) had
an FEV1o35%. On echocardiographic examinations,
COPD patients had increased interventricular sep-
tum thickness. They also had lower ejection
fraction (EF) and fractional shortening (FS) com-
pared to controls (Table 1). However, none of the
COPD patients had systolic dysfunction (EFo50%
and/or FSo25%). Left ventricular posterior wall
thickness (LVPW), left ventricular mass index
(LVMI), left atrial diameter, and heart rate were
similar between COPD patients and controls.
Decreased mitral E/A ratio (0.807 0.17 vs.
1.227 0.29, P ¼ 0:003), and increased IVRT
(1377 18 vs. 777 13ms, P ¼ 0:004) were found
in COPD patients, compared to controls. Diastolic
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dysfunction was found in 94% of our COPD patient
and E/A ratio correlated with Ppa (r ¼ 0.45,
P ¼ 0:013).
Pulmonary artery pressure was measured non-
invasively by echocardiography examination in the
presence of tricuspid valve insufficiency (n: 38).
Pulmonary artery pressure greater than 25mmHg
was accepted as pulmonary hypertension and
patients were subdivided into two groups according
to the presence (n: 24) or absence (n: 14) of
pulmonary hypertension. Patients with pulmonary
hypertension had increased age, lower PaO2, lower
predicted FEV1 and lower FEV1/FVC levels as
compared to COPD patients without pulmonary
hypertension. Right ventricular free wall thickness
(0.757 0.01 vs. 0.687 0.01 cm, P ¼ 0:03) and
right ventricular diameter in diastole (2.87 0.3
vs. 2.57 0.2 cm, Po0.001) were also increased in
patients with pulmonary hypertension. Pulmonary
hypertension patients also had increased left
atrium diameter and heart rate. Other respiratory
function tests, arterial blood gas parameters and
left ventricular mass indexes were found to be
similar in COPD patients with and without pulmon-
ary hypertension (Table 2).
Distributions of ACE and eNOS genotypes were
similar in COPD patients and controls (Table 1).
When comparing pulmonary artery pressures in
different eNOS genotypes, the mean pulmonary
artery pressure (Ppa) in patients with the BB
genotype was significantly higher than in patients
with the nonBB genotypes (41.37 17.7 vs.
27.37 11.2mmHg, P¼ 0.02). Patients with pul-
monary hypertension had a higher prevalence rate
of BB eNOS genotypes compared to patients with-
out pulmonary hypertension (83% vs. 50%,
P¼ 0.036). However, there was no difference in
ACE genotype distributions when comparing COPD
patients with and without pulmonary hypertension
(Table 2). Additionally, pulmonary artery pressures
were found to be similar among ACE genotypes
(337 12mmHg for DD, 417 20mmHg for DI and
307 9mmHg for II, P40:05) (Fig. 1).
Pulmonary artery pressure was correlated with age
(r ¼ 0:37; P ¼ 0:02), PaO2 (r ¼  0:36; P ¼ 0:02),
and smoking (total pack-years) (r ¼ 0:34; P ¼ 0:04).
In a stepwise linear regression analysis for
predicting pulmonary artery pressure (model r ¼
0:52; P ¼ 0:004), PaO2 (standardized b: 0.36
(0.73 to 0.08; 95% CI for b, P ¼ 0:02) and
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Table 1 Results of respiratory function tests, arterial blood gases and echocardiographic examinations.
COPD n: 42 Control n: 40 Statistics
VC (%) 64721 95710 o0.001
FVC (%) 60722 97711 o0.001
FEV1 (%) 42719 101710 o0.001
FEV1/FVC 55711 8674 o0.001
pH 7:4070:04 F
pO2 (mmHg) 69716 F
pCO2 (mmHg) 4277 F
HCO3 (mmol/l) 2573 F
Heart rate (bpm) 82717 78711 NS
RVPW(cm) 0:7370:10 0:7170:09 o0.01
Rvdiameter 2:6570:28 2:2070:67 o0.001
IVSd (cm) 1:170:1 0:9570:13 0.003
LVPW (cm) 1:070:1 0:9570:20 NS
LVMI (g/m2) 116723 89722 NS
IVRT (ms) 137718 77713 0.004
Mitral E/A ratio 0:8070:17 1:2270:29 0.003
EF (%) 6374 7175 o0.001
FS (%) 3473 4076 o0.001
eNOS gene polymorphism
BB 31 33
nonBB 11 7 NS
ACE gene polymorphism
DD 14 12
DI 21 18
II 7 10 NS
IVSd: interventricular septum thickness in diastole, LVPW: left ventricular posterior wall, LVMI: left ventricular mass index, IVRT:
isovolumetric relaxation time, FS: fractional shortening.
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polymorphism of eNOS gene (standardized b: 0.33
(1.47–23.5; 95% CI for b, P ¼ 0:03) were found to be
independent variables.
Discussion
eNOS derived NO is an important modulator of the
pulmonary vascular response to a different vaso-
constrictor stimuli, including chronic hypoxia.26
eNOS-deficient mice have progressive pulmonary
hypertension and right ventricular hypertrophy
after chronic hypoxia.11,12 In contrast, mice over-
expressing eNOS are protected from developing
hypoxia-induced pulmonary hypertension and vas-
cular remodeling.27 It was also shown that the eNOS
system is abnormal in patients with PH.7,8 Although
previous studies support a role for eNOS in
modulating the chronic pulmonary vascular re-
sponse to hypoxia, the exact mechanism by which
hypoxia decreases eNOS expression is not known. In
this study, there was no difference in eNOS
genotype distribution between COPD patients and
controls. However, patients with BB genotype had
higher pulmonary artery pressure on echocardio-
graphy examination and this association was re-
tained in linear regression analysis. Our data
suggest that eNOS gene polymorphism might be
associated with PH in COPD patients and might be a
genetic predictor of in situ NO expression.
Angiotensin II, a strong vasoconstrictor agent, is
an important molecule in maintaining vasomotor
tone of the vascular bed. It has been shown that
deletion type polymorphism of ACE gene has been
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Table 2 Comparisons between COPD patients with and without pulmonary hypertension.
Patients with PH
(425mmHg)
Patients without PH
(o25mmHg)
Age 6274:8 5777:3 0.02
PaO2 66714 76717 0.078
PaCO2 4377:9 4074:8 NS
FEV1 (%pred) 40718 49722 NS
FEV1/FVC ratio 54712 58712 NS
RVPW(cm) 0:7570:001 0:6870:001 0.032
RV diameter 2:870:3 2:570:2 o0.001
LA diameter 3:670:4 3:270:3 0.002
IVSd (cm) 1:170:1 1:170:1 NS
LVPW (cm) 1:0370:1 0:9971:11 NS
EF (%) 6176:5 6373:9 NS
Heart rate 86720 7577:4 0.045
LVMI (g/m2) 122727 109720 NS
FS (%) 3277 3473 NS
IVRT (ms) 137720 132715 NS
E/A ratio 0:7370:14 0:9070:17 0.006
PAP (mmHg) 47715 2173 o0.001
ACE genotype
DD 29% (n: 7) 29% (n: 4)
NonDD 71% (n: 17) 71% (n: 10) NS
eNOS genotype
AB 17% (n: 4) 50% (n: 7)
BB 83% (n: 20) 50% (n: 7) 0.036
Figure 1 The results of the pulmonary artery pressure in
different ACE and eNOS genotypes in COPD patients. DD:
homozygous deletion polymorphism of the angiotensin
converting enzyme gene; DI: heterozygous deletion–inser-
tion polymorphism of the ACE gene; II: homozygous
insertion type polymorphism of the ACE gene; BB: BB
homozygous genotype of intron 4 VNTR polymorphism of
the endothelial nitric oxide synthase gene; NonBB: AB
heterozygous or AA homozygous genotypes of intron 4 VNTR
polymorphism of the endothelial nitric oxide synthase gene.
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associated with higher levels of AII.15 It is known
that the renin angiotensin system plays an impor-
tant role in the development of pulmonary artery
remodeling and right ventricular hypertrophy in
hypoxia-induced pulmonary hypertension. How-
ever, there is limited data for a possible relation-
ship between ACE gene polymorphism and PH.
Kanazawa et al.14 reported that mean pulmonary
artery pressure after exercise in patients with the
DD genotype was significantly higher than in
patients with the II genotype. However, no
difference was found between ID and DD geno-
types. The mean Ppa at rest in the different
ACE genotypes was not significantly different. In
that study, invasive monitoring had been used
for measuring pulmonary artery pressure. In our
study, pulmonary artery pressure and right ventri-
cular diameter were not different while resting
in patients with the different ACE genotypes,
which was consistent with results of Kanazawa
et al.14
In our study, COPD patients had increased IVSd
and decreased left ventricular EF without causing
overt systolic left ventricular dysfunction. These
findings were consistent with previous reports.28–31
Previous studies have shown that LV diastolic
impairment related to pulmonary hypertension
due to chronic obstructive pulmonary disease.32–34
Diastolic dysfunction was found in most of our COPD
patient and correlated with pulmonary pressure.
Hypoxia leads to vasoconstriction in pulmonary
vasculature; hence it provided ventilation-perfu-
sion matching in pulmonary circulation. It has been
shown in numerous studies that hypoxia has
important role on development of pulmonary
hypertension in COPD patients.26,35 In our study,
patients with PH have lower PaO2 levels and
pulmonary artery pressure was negatively corre-
lated with PaO2. In a linear regression analysis,
PaO2 was found to be an independent variable for
predicting PH in COPD patients.
In the present study, noninvasive pulsed Doppler
echocardiography was utilized to estimate pulmon-
ary artery pressure in COPD patients, as it has been
done in some previous reports.36,37 However, right
ventricular catheterization is the gold standard
technique to measure pulmonary artery pressure in
this group of patients.38 In addition, most of our
patients (61%) had mild-to-moderate COPD. We
performed all blood gases analyses in the resting
condition and some patients had near normal blood
O2 levels at rest. We did not perform blood gas
analysis and measurement of pulmonary artery
pressure during exercise, which is another limita-
tion of the study. There is need for further studies
to investigate the influence of eNOS genotypes
on pulmonary artery pressure during short-term
exercise.
In conclusion, BB-type polymorphism of the eNOS
gene has been associated with PH in addition to
hypoxemia. However, ACE gene polymorphism was
not found to be associated with PH. eNOS gene
polymorphism might have a role in the develop-
ment of PH in COPD patients.
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